Ciprofloxacin News and Research

RSS

Aradigm’s Lipoquin provides full protection in murine models of pneumonic plague

Scientists from the UK Defence Science and Technology Laboratory (Dstl) report, in a preliminary study, that they have demonstrated that a single dose of Aradigm Corporation's liposomal ciprofloxacin formulation Lipoquin administered 24 hours after exposure to a lethal dose of the bacterium Yersinia pestis provided full protection in a murine model of pneumonic plague.

20 Nov 2012

Ciprofloxacin use is major contributor to MRSA spread in hospitals

The use of a commonly prescribed antibiotic is a major contributor to the spread of infection in hospitals by the 'superbug' MRSA, according to new research. The study also found that increasing measures to prevent infection - such as improved hygiene and hand washing - appeared to have only a small effect on reducing MRSA infection rates during the period studied.

21 Sep 2012

Positive results from Santarus rifamycin SV MMX Phase III study on travelers' diarrhea

Santarus, Inc. today announced that its Phase III clinical study to evaluate the safety and efficacy of the investigational drug, rifamycin SV MMX, met the primary endpoint of reducing time to last unformed stool (TLUS) in patients with travelers' diarrhea.

12 Sep 2012

Kalidex announces presentation of data on KPI-10 against MDR strains at ICAAC

Kalidex Pharmaceuticals, a privately-held anti-infective company, today announced the presentation of data on its lead development candidate KPI-10, a broad spectrum, next-generation fluoroquinolone, at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, September 9 through 12.

7 Sep 2012

Researchers reveal possible drug targets to combat anthrax

A trawl of the genome of the deadly bacterium Bacillus anthracis has revealed a clutch of targets for new drugs to combat an epidemic of anthrax or a biological weapons attack.

21 Aug 2012

One-week ciprofloxacin effective for pyelonephritis

Treatment for 7 days with the antibiotic ciprofloxacin is as effective at treating acute pyelonephritis in women as a 14-day regimen of the fluoroquinolone, with a similar safety profile, report Swedish researchers.

17 Aug 2012

Special device provides evidence of how bloodstream infections begin

New research may help explain why hundreds of thousands of Americans a year get sick - and tens of thousands die - after bacteria get into their blood. It also suggests why some of those bloodstream infections resist treatment with even the most powerful antibiotics.

16 Aug 2012

Non-antibiotic compounds can prevent urinary tract infections

The latest episode in the American Chemical Society's (ACS') award-winning Global Challenges/Chemistry Solutions podcast series describes a potential new approach for treating urinary tract infections (UTIs) - which affect millions of people annually - without traditional antibiotics. Because it involves non-antibiotic compounds, the approach would not contribute to the growing problem of antibiotic-resistant bacteria, or "superbugs."

16 Aug 2012

Common antibiotics may risk liver injury in elderly

Regulatory warnings should be considered for the antibiotics moxifloxacin and levofloxacin because of a potential risk for liver injuries in the elderly, Canadian researchers suggest.

14 Aug 2012

Boric acid treatment equals best practice for otitis media

Study findings show that a single application of boric acid powder followed by external auditory canal irrigation is as effective as topical ciprofloxacin eardrops for treating active chronic otitis media.

6 Aug 2012

FimH antagonists can effectively treat UTIs

A potential new approach for treating urinary tract infections (UTIs) - which affect millions of people annually - without traditional antibiotics is being reported in ACS' Journal of Medicinal Chemistry. It involves so-called FimH antagonists, which are non-antibiotic compounds and would not contribute to the growing problem of antibiotic resistance bacteria.

21 Jun 2012

Aradigm first quarter total revenue increases to $0.3 million

Aradigm Corporation today announced financial results for the first quarter and three months ended March 31, 2012.

11 May 2012

Ciprofloxacin, TMP-SMX no longer safe for outpatient urinary tract infection

In a surveillance study of over 12 million bacteria, investigators at The George Washington University and Providence Hospital found E. coli antimicrobial resistance to ciprofloxacin, the most commonly prescribed antimicrobial for urinary tract infections in the U.S., increased over five-fold from 2000 to 2010.

2 May 2012

FDA clears Aradigm IND for Pulmaquin Phase 3 clinical trial in non-cystic fibrosis BE

Aradigm Corporation today announced that the Company's Investigational New Drug Application (IND) to conduct a pivotal Phase 3 clinical trial of Pulmaquin (dual release ciprofloxacin for inhalation) in non-cystic fibrosis bronchiectasis (BE) has been cleared by the U.S. Food and Drug Administration.

12 Mar 2012

State news: Ore. Gov. signs reform bill; Texas seeks early release of sick inmates

If Oregon's Democratic governor is right, the bill he signed Friday will improve health care and reduce costs so significantly that it could help fix the federal budget. The Obama administration is watching with keen interest -; and so are critics who say Gov. John Kitzhaber's plan is just another example of government overreach.

6 Mar 2012

Roundup: Iowa lawmaker urges waiting on exchange bill until court rules; Calif. group finds way to recycle medicine

Democrats and Republicans disagree about whether the Legislature needs to approve a health insurance exchange this spring. At a Statehouse forum on the issue Thursday, state Sen. Brad Zaun noted that the U.S. Supreme Court is expected to rule this summer on whether major portions of the health reform law are constitutional. Zaun, an Urbandale Republican who opposes the overall law, said it makes sense to wait until after that decision before deciding whether to move ahead with the exchange.

3 Mar 2012

Cefpodoxime not effective in treating uncomplicated cystitis in women

Short-term use of the antibiotic cefpodoxime for the treatment of women with uncomplicated cystitis (bladder infection) did not meet criteria for noninferiority for achieving clinical cure compared with ciprofloxacin, a drug in the fluoroquinolone class of antibiotics for which there have been concerns about overuse and a resulting increase in resistance rates, according to a study in the February 8 issue of JAMA.

8 Feb 2012

DNA gyrase B could rapidly eliminate TB, shorten treatment time

In research at SRI International, scientists evaluating new drug targets against tuberculosis (TB) recently validated the preclinical effectiveness of a target that could rapidly eliminate infections and potentially shorten treatment time. The new drug target is a protein called DNA gyrase B, found in bacteria that cause TB infections.

30 Nov 2011

Two-drug combination may alleviate radiation sickness in people

A combination of two drugs may alleviate radiation sickness in people who have been exposed to high levels of radiation, even when the therapy is given a day after the exposure occurred, according to a study led by scientists from Dana-Farber Cancer Institute and Children's Hospital Boston.

24 Nov 2011

Panel backs anthrax vaccine testing on children

An important panel of government advisers Friday recommended that the government should sponsor a controversial study to test the anthrax vaccine in children to see whether the inoculation would protect young Americans against a bioterrorist's attack.

31 Oct 2011